financetom
Business
financetom
/
Business
/
Ollie's Bargain Outlet Holdings Insider Sold Shares Worth $381,733, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ollie's Bargain Outlet Holdings Insider Sold Shares Worth $381,733, According to a Recent SEC Filing
Apr 8, 2025 3:17 PM

05:56 PM EDT, 04/08/2025 (MT Newswires) -- John W Swygert, Director, Executive Chairman, on April 04, 2025, sold 3,331 shares in Ollie's Bargain Outlet Holdings (OLLI) for $381,733. Following the Form 4 filing with the SEC, Swygert has control over a total of 48,200 common shares of the company, with 48,200 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1639300/000121390025030009/xslF345X05/marketforms-69110.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Cato Keeps Quarterly Dividend at $0.17 per share, Payable June 24 to Shareholders of Record June 10
--Cato Keeps Quarterly Dividend at $0.17 per share, Payable June 24 to Shareholders of Record June 10
May 24, 2024
08:17 AM EDT, 05/24/2024 (MT Newswires) -- Price: 5.73, Change: -0.05, Percent Change: -0.87 ...
E3 Lithium Narrows Q1 Loss; Company Hasn't Started Commercial Production or Generated Cash Flow
E3 Lithium Narrows Q1 Loss; Company Hasn't Started Commercial Production or Generated Cash Flow
May 24, 2024
08:25 AM EDT, 05/24/2024 (MT Newswires) -- E3 Lithium ( EEMMF ) on Friday reported a narrower loss for the first quarter even though the company has not generated revenues from operations and had an accumulated deficit of $45.2 million at the end of March. The company reported a first-quarter net loss of $2.4 million, or $0.03 per share, compared...
Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer
Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer
May 24, 2024
08:25 AM EDT, 05/24/2024 (MT Newswires) -- Verastem Oncology (VSTM) late Thursday reported that an ongoing phase 1/2 clinical trial evaluating avutometinib and defactinib in combination with gemcitabine and nab-paclitaxel in 41 patients with metastatic pancreatic cancer reached an interim partial response rate of 83%. Of 26 patients in all the trial cohorts who have had their first scan while...
Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation
Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation
May 24, 2024
08:17 AM EDT, 05/24/2024 (MT Newswires) -- Organon (OGN) and Shanghai Henlius Biotech said Friday their marketing authorization applications for HLX14, a denosumab biosimilar, have been validated by the European Medicines Agency. The submissions were based on a phase 3 study comparing HLX14 with denosumab in postmenopausal women with osteoporosis, the companies said. Henlius licensed HLX14 to Organon in 2022...
Copyright 2023-2025 - www.financetom.com All Rights Reserved